Revenue
2016
2017
2018
2019
2022
2023
2024
2025
Autolus Therapeutics plc (AUTL)
Price$2.24Cached quote
Net income
2016
2017
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2016
2017
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 · Dec 31 | 2017 · Sep 30 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $75.4M | $10.1M | $1.7M | $6.2M | — | — | $2.9M | $1.4M | — | $1.7M | $1.2M |
| Gross profit | −$21.0M | −$1.3M | $1.7M | — | — | — | — | — | — | — | — |
| Gross margin | −27.83% | −12.52% | 100.00% | — | — | — | — | — | — | — | — |
| Research & development | $117.7M | $138.4M | $130.5M | $117.4M | $110.8M | $134.9M | $105.4M | $36.1M | — | $16.0M | $10.4M |
| Operating expenses | $249.6M | $240.2M | $181.4M | $149.1M | — | — | — | $57.5M | — | $23.4M | $14.4M |
| Operating income | −$270.5M | −$241.4M | −$179.7M | −$143.4M | −$141.1M | −$168.1M | −$146.1M | −$57.5M | — | −$23.4M | — |
| Operating margin | −358.87% | −2,385.63% | −10,583.10% | −2,315.27% | — | — | −5,022.83% | −4,089.05% | — | −1,383.23% | — |
| EBITDA | −$262.2M | −$233.9M | −$173.1M | −$136.0M | −$132.6M | −$162.5M | −$141.5M | −$55.8M | — | −$22.4M | — |
| EBITDA margin | −347.86% | −2,310.99% | −10,196.47% | −2,195.45% | — | — | −4,864.27% | −3,967.59% | — | −1,323.63% | — |
| Net income | −$287.5M | −$220.7M | −$208.4M | −$148.8M | −$142.1M | −$142.1M | −$123.8M | −$44.8M | −$19.7M | −$19.7M | −$12.6M |
| Net profit margin | −381.40% | −2,180.45% | −12,272.26% | −2,402.95% | — | — | −4,258.91% | −3,180.60% | — | −1,165.21% | −1,035.48% |
| Basic EPSper basic share | -$1.08 | -$0.86 | -$1.20 | -$1.57 | -$1.97 | -$2.76 | -$2.88 | -$1.42 | — | -$1.43 | -$1.26 |
| Diluted EPSper diluted share | -$1.08 | -$0.86 | -$1.20 | -$1.57 | -$1.97 | -$2.76 | -$2.88 | -$1.42 | — | -$1.43 | -$1.26 |
Owners
Reported shareholders
Reported holdings Number of shares
View holders
| Holder | Shares held |
|---|---|
MAK CAPITAL ONE LLC | 33.62M |
Blackstone Inc. | 20.49M |
Syncona Portfolio Ltd | 16.64M |
ARMISTICE CAPITAL, LLC | 15M |
Tetragon Partners GP Ltd | 9.5M |
SCHRODER INVESTMENT MANAGEMENT GROUP | 7.83M |
Frazier Life Sciences Management, L.P. | 4.45M |
BNP PARIBAS ASSET MANAGEMENT Holding S.A. | 3.36M |
Laurion Capital Management LP | 3.32M |
RENAISSANCE TECHNOLOGIES LLC | 1.98M |
BANK OF AMERICA CORP /DE/ | 1.61M |
BlackRock, Inc. | 1.6M |
UBS Group AG | 1.52M |
MORGAN STANLEY | 1.26M |
MILLENNIUM MANAGEMENT LLC | 1.22M |
Cetera Investment Advisers | 1.16M |
Itin Christian | 1.12M |
Balyasny Asset Management L.P. | 972.75K |
JPMORGAN CHASE & CO | 913.24K |
Alphabet Inc. | 698.26K |
Bars compare reported share counts. A matching total for this share class and reporting period is unavailable, so percentages are not shown.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data